BFC
PRVB

Bedel Financial Consulting’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Bedel Financial Consulting’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-251
Closed -$1K – 1095
2021
Q4 		$1K Hold
251
– – ﹤0.01% 993
2021
Q3 		$2K Hold
251
– – ﹤0.01% 912
2021
Q2 		$2K Hold
251
– – ﹤0.01% 905
2021
Q1 		$3K Buy
+251
New +$3.53K ﹤0.01% 827

Other funds holding PRVB

SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return

Bedel Financial Consulting's PRVB Position: Q1 2022 in Review

Bedel Financial Consulting sold out of Provention Bio, Inc. Common Stock (PRVB) in Q1 2022, closing a stake of 251 shares — an estimated $1K sold.

Bedel Financial Consulting first reported a position in PRVB in Q1 2021 and held it in 4 quarters. The position peaked at $3K in Q1 2021. 113 funds tracked by Wall St. Rank hold PRVB as of Q1 2022.

  • Bedel Financial Consulting reported no remaining Provention Bio, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Bedel Financial Consulting sold 251 Provention Bio, Inc. Common Stock shares in Q1 2022, an estimated $1K.
  • Bedel Financial Consulting first reported a position in Provention Bio, Inc. Common Stock in Q1 2021 and held it in 4 quarters.
  • Bedel Financial Consulting's Provention Bio, Inc. Common Stock position peaked at $3K in Q1 2021.
  • 113 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q1 2022.

Based on Bedel Financial Consulting's 13F filing for Q1 2022, filed 19 Apr 2022.